Guanfacine Extended Release (GXR) is being evaluated for its efficacy in reducing aggression and self-injurious behavior in individuals with Prader-Willi Syndrome (PWS). This clinical trial, sponsored by Maimonides Medical Center, addresses a significant unmet need in the management of behavioral symptoms associated with PWS, a genetic disorder affecting appetite and behavior. If successful, GXR could capture a niche market within the pediatric and adolescent populations suffering from PWS, potentially expanding its use beyond its current FDA-approved indications for hypertension and ADHD. The competitive landscape includes other behavioral interventions and pharmacotherapies, but GXR's specific targeting of aggression and self-injury in PWS may provide a unique selling proposition. Diligence should focus on the trial's safety profile and metabolic effects, as these will be critical for market acceptance and physician adoption.